Waterstone Capital Management L.P. reduced its position in shares of Hologic, Inc. (NASDAQ:HOLX) by 7.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 391,200 shares of the medical equipment provider’s stock after selling 29,300 shares during the period. Hologic accounts for about 9.3% of Waterstone Capital Management L.P.’s portfolio, making the stock its 4th largest holding. Waterstone Capital Management L.P. owned 0.14% of Hologic worth $14,353,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Koch Industries Inc. grew its position in shares of Hologic by 15,554.1% in the second quarter. Koch Industries Inc. now owns 1,149,481 shares of the medical equipment provider’s stock valued at $1,125,000 after purchasing an additional 1,142,138 shares in the last quarter. Picton Mahoney Asset Management grew its position in shares of Hologic by 8.1% in the second quarter. Picton Mahoney Asset Management now owns 57,150 shares of the medical equipment provider’s stock valued at $2,593,000 after purchasing an additional 4,300 shares in the last quarter. Swiss National Bank grew its position in shares of Hologic by 12.8% in the second quarter. Swiss National Bank now owns 1,159,424 shares of the medical equipment provider’s stock valued at $52,615,000 after purchasing an additional 131,300 shares in the last quarter. Rhumbline Advisers grew its position in shares of Hologic by 1.4% in the second quarter. Rhumbline Advisers now owns 548,465 shares of the medical equipment provider’s stock valued at $24,889,000 after purchasing an additional 7,727 shares in the last quarter. Finally, Robeco Institutional Asset Management B.V. grew its position in shares of Hologic by 68.5% in the second quarter. Robeco Institutional Asset Management B.V. now owns 42,267 shares of the medical equipment provider’s stock valued at $1,919,000 after purchasing an additional 17,180 shares in the last quarter. Institutional investors own 98.09% of the company’s stock.

Hologic, Inc. (HOLX) opened at $41.44 on Thursday. The firm has a market capitalization of $11,548.39, a P/E ratio of 20.74, a P/E/G ratio of 2.03 and a beta of 0.95. Hologic, Inc. has a 52-week low of $35.76 and a 52-week high of $46.80. The company has a debt-to-equity ratio of 0.79, a current ratio of 0.79 and a quick ratio of 0.61.

Hologic (NASDAQ:HOLX) last issued its quarterly earnings data on Wednesday, November 8th. The medical equipment provider reported $0.50 earnings per share for the quarter, topping the consensus estimate of $0.49 by $0.01. The company had revenue of $802.90 million during the quarter, compared to analyst estimates of $792.54 million. Hologic had a return on equity of 21.69% and a net margin of 24.70%. The firm’s revenue for the quarter was up 10.5% compared to the same quarter last year. During the same period in the prior year, the business posted $0.52 earnings per share. analysts anticipate that Hologic, Inc. will post 2.12 EPS for the current fiscal year.

In related news, Director Lawrence M. Levy sold 7,138 shares of the stock in a transaction that occurred on Monday, October 9th. The stock was sold at an average price of $37.38, for a total value of $266,818.44. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence M. Levy sold 9,596 shares of the stock in a transaction that occurred on Tuesday, October 10th. The stock was sold at an average price of $36.81, for a total value of $353,228.76. The disclosure for this sale can be found here. Insiders sold 28,833 shares of company stock valued at $1,107,270 over the last quarter. 0.79% of the stock is currently owned by company insiders.

A number of research firms have recently issued reports on HOLX. Piper Jaffray Companies restated a “buy” rating and issued a $48.00 price target on shares of Hologic in a research report on Thursday, November 9th. Barclays restated an “equal weight” rating and issued a $51.00 price target (down from $53.00) on shares of Hologic in a research report on Wednesday, August 9th. Royal Bank Of Canada restated a “hold” rating and issued a $42.00 price target on shares of Hologic in a research report on Friday, September 22nd. BidaskClub lowered Hologic from a “hold” rating to a “sell” rating in a research report on Wednesday, August 9th. Finally, Zacks Investment Research upgraded Hologic from a “sell” rating to a “hold” rating in a research report on Tuesday, October 31st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and nine have assigned a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $47.38.

WARNING: “Waterstone Capital Management L.P. Cuts Holdings in Hologic, Inc. (HOLX)” was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this piece on another domain, it was illegally copied and reposted in violation of U.S. & international copyright legislation. The legal version of this piece can be viewed at https://www.watchlistnews.com/waterstone-capital-management-l-p-cuts-holdings-in-hologic-inc-holx/1748864.html.

About Hologic

Hologic, Inc is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products with an emphasis on women’s health. The Company operates through four segments: Diagnostics, Breast Health, GYN Surgical and Skeletal Health. The diagnostics products include Aptima family of assays, ThinPrep system, the Rapid Fetal Fibronectin Test and Procleix blood screening assays.

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.